1
|
Schweitzer A, Horn J, Mikolajczyk RT, Krause G and Ott JJ: Estimations of worldwide prevalence of chronic hepatitis B virus infection: A systematic review of data published between 1965 and 2013. Lancet. 386:1546–1555. 2015.PubMed/NCBI View Article : Google Scholar
|
2
|
Mohd Hanafiah K, Groeger J, Flaxman AD and Wiersma ST: Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatology. 57:1333–1342. 2013.PubMed/NCBI View Article : Google Scholar
|
3
|
Chung H, Ueda T and Kudo M: Changing trends in hepatitis C infection over the past 50 years in Japan. Intervirology. 53:39–43. 2010.PubMed/NCBI View Article : Google Scholar
|
4
|
de Martel C, Maucort-Boulch D, Plummer M and Franceschi S: World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. Hepatology. 62:1190–1200. 2015.PubMed/NCBI View Article : Google Scholar
|
5
|
Su TH and Kao JH: Improving clinical outcomes of chronic hepatitis B virus infection. Expert Rev Gastroenterol Hepatol. 9:141–154. 2015.PubMed/NCBI View Article : Google Scholar
|
6
|
Yokosuka O, Takaguchi K, Fujioka S, Shindo M, Chayama K, Kobashi H, Hayashi N, Sato C, Kiyosawa K, Tanikawa K, et al: Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection. J Hepatol. 52:791–799. 2010.PubMed/NCBI View Article : Google Scholar
|
7
|
Ono A, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Saitou S, Arase Y, et al: Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients. J Hepatol. 57:508–514. 2012.PubMed/NCBI View Article : Google Scholar
|
8
|
Sugiyama A, Ohisa M, Nagashima S, Yamamoto C, Chuon C, Fujii T, Akita T, Katayama K, Kudo Y and Tanaka J: Reduced prevalence of hepatitis B surface antigen positivity among pregnant women born after the national implementation of immunoprophylaxis for babies born to hepatitis B virus-carrier mothers in Japan. Hepatol Res. 47:1329–1334. 2017.PubMed/NCBI View Article : Google Scholar
|
9
|
de Fraga RS, Van Vaisberg V, Mendes LCA, Carrilho FJ and Ono SK: Adverse events of nucleos(t)ide analogues for chronic hepatitis B: A systematic review. J Gastroenterol. 55:496–514. 2020.PubMed/NCBI View Article : Google Scholar
|
10
|
Kumada H, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, Kawakami Y, Ido A, Yamamoto K, Takaguchi K, et al: Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 59:2083–2091. 2014.PubMed/NCBI View Article : Google Scholar
|
11
|
Omata M, Nishiguchi S, Ueno Y, Mochizuki H, Izumi N, Ikeda F, Toyoda H, Yokosuka O, Nirei K, Genda T, et al: Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: An open-label, phase 3 trial. J Viral Hepat. 21:762–768. 2014.PubMed/NCBI View Article : Google Scholar
|
12
|
Chayama K, Notsumata K, Kurosaki M, Sato K, Rodrigues L Jr, Setze C, Badri P, Pilot-Matias T, Vilchez RA and Kumada H: Randomized trial of interferon- and ribavirin-free Ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients. Hepatology. 61:1523–1532. 2015.PubMed/NCBI View Article : Google Scholar
|
13
|
Mizokami M, Yokosuka O, Takehara T, Sakamoto N, Korenaga M, Mochizuki H, Nakane K, Enomoto H, Ikeda F, Yanase M, et al: Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: An open-label, randomised, phase 3 trial. Lancet Infect Dis. 15:645–653. 2015.PubMed/NCBI View Article : Google Scholar
|
14
|
Suda G, Furusyo N, Toyoda H, Kawakami Y, Ikeda H, Suzuki M, Arataki K, Mori N, Tsuji K, Katamura Y, et al: Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: A nationwide retrospective study in Japan. J Gastroenterol. 53:119–128. 2018.PubMed/NCBI View Article : Google Scholar
|
15
|
Akuta N, Sezaki H, Suzuki F, Kawamura Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, et al: Favorable efficacy of daclatasvir plus asunaprevir in treatment of elderly Japanese patients infected with HCV genotype 1b aged 70 and older. J Med Virol. 89:91–98. 2017.PubMed/NCBI View Article : Google Scholar
|
16
|
Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, et al: Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology. 140:132–143. 2011.PubMed/NCBI View Article : Google Scholar
|
17
|
Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Aguilar Schall R, et al: Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: A 5-year open-label follow-up study. Lancet. 381:468–475. 2013.PubMed/NCBI View Article : Google Scholar
|
18
|
Backus LI, Belperio PS, Shahoumian TA and Mole LA: Impact of sustained virologic response with direct-acting antiviral treatment on mortality in patients with advanced liver disease. Hepatology. 69:487–497. 2019.PubMed/NCBI View Article : Google Scholar
|
19
|
Nagai K, Ide K, Kawasaki Y, Tanaka-Mizuno S, Seto K, Iwane S, Eguchi Y and Kawakami K: Estimating the cost-effectiveness of screening for hepatitis C virus infection in Japan. Hepatol Res. 50:542–556. 2020.PubMed/NCBI View Article : Google Scholar
|
20
|
El-Serag HB, Kanwal F, Richardson P and Kramer J: Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. Hepatology. 64:130–137. 2016.PubMed/NCBI View Article : Google Scholar
|
21
|
Orito E, Ichida T, Sakugawa H, Sata M, Horiike N, Hino K, Okita K, Okanoue T, Iino S, Tanaka E, et al: Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. Hepatology. 34:590–594. 2001.PubMed/NCBI View Article : Google Scholar
|
22
|
Toyoda H, Kumada T, Takaguchi K, Shimada N and Tanaka J: Changes in hepatitis C virus genotype distribution in Japan. Epidemiol Infect. 142:2624–2628. 2014.PubMed/NCBI View Article : Google Scholar
|
23
|
Ikeda K, Saitoh S, Koida I, Arase Y, Tsubota A, Chayama K, Kumada H and Kawanishi M: A multivariate analysis of risk factors for hepatocellular carcinogenesis: A prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology. 18:47–53. 1993.PubMed/NCBI
|
24
|
Ministry of Health, Labour and Welfare: Basic guidelines for promotion of control measures for hepatitis. http://www.mhlw.go.jp/bunya/kenkou/kekkakukansenshou09/pdf/hourei-17e.pdf. Accessed August 21, 2017.
|
25
|
Tatemichi M, Furuya H, Nagahama S, Takaya N, Shida Y, Fukai K, Owada S, Endo H, Kinoue T and Korenaga M: A nationwide cross-sectional survey on hepatitis B and C screening among workers in Japan. Sci Rep. 10(11435)2020.PubMed/NCBI View Article : Google Scholar
|
26
|
Gender Equality Bureau, Cabinet Office, Government of Japan: White Paper on Gender Equality 2020-Summary. 2020. https://www.gender.go.jp/english_contents/about_danjo/whitepaper/pdf/ewp2020.pdf. Accessed July 31. 2020.
|
27
|
Sasaki T, Izawa M and Okada Y: Current trends in health insurance systems: OECD countries vs. Japan. Neurol Med Chir (Tokyo). 55:267–275. 2015.PubMed/NCBI View Article : Google Scholar
|